Cargando…

Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements

In many phase II trials in solid tumours, patients are assessed using endpoints based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale. Often, analyses are based on the response rate. This is the proportion of patients who have an observed tumour shrinkage above a predefined level...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chien‐Ju, Wason, James M.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724692/
https://www.ncbi.nlm.nih.gov/pubmed/28850689
http://dx.doi.org/10.1002/sim.7453